PRLD Prelude Therapeutics

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences.

Details are as follows:

  • H. C. Wainwright BioConnect Investor Conference at Nasdaq

    Kris Vaddi, Ph.D., Chief Executive Officer will participate in a fireside chat on Tuesday, May 2, at 1:30 p.m. ET. The live webcast is available . The Company will also host one-on-one investor meetings during the day.

  • Bank of America Securities 2023 Healthcare Conference

    Jane Huang, MD, President and Chief Medical Officer and Laurent Chardonnet, Chief Financial Officer, will conduct one-on-one meetings on Wednesday, May 10 and Thursday May 11. Dr. Huang will participate in a fireside chat on May 10 at 4:20 p.m. PT/7:20 p.m. ET. The live webcast will be available , and will be available for replay until August 11, 2023.

  • JMP Securities Life Sciences Conference

    Dr. Vaddi and Mr. Chardonnet will conduct one-on-one meetings on Monday, May 15 and Tuesday May 16 and Dr. Vaddi will participate in a fireside chat at 12 noon ET, on May 15. The live webcast is available and will be available for replay for 90 days.

About Prelude Therapeutics 

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best-in-class or first-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a next generation CDK4/6 inhibitor, and PRT3789, an IV administered, potent and highly selective SMARCA2 degrader.

For more information, visit our and follow us on and .

Investor Contact: 

Lindsey Trickett 

Vice President, Investor Relations 

240.543.7970 

Media Contact: 

Helen Shik  

Shik Communications  

617.510.4373





EN
27/04/2023

Underlying

PRLDPrelude Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Prelude Therapeutics

 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and...

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025 Phase 1 study of PRT3789, a once weekly IV SMARCA2 degrader, has been completed; Company to provide final data by year end 2025 Prelude is advancing a development candidate for its oral KAT6A degrader program and remains on track to file an IND in the first half o...

August 14, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2025:On Thursday, June 5, 2025, at 3:10 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. Goldman Sachs 46th Annual Global Healthcare Conference:On Wednesday, June 11, 2025, at 9:20 a.m. ET, Kris, Vaddi, Ph.D., ...

June 2, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Reports First Quarter 2025 Financial Results and ...

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude’s once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with $103.1 million in cash, cash equivalents, restricted cash and marketable securities as of March 31...

May 6, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics to Participate in Citizens Life Sciences Conferen...

Prelude Therapeutics to Participate in Citizens Life Sciences Conference WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025. On Wednesday, May 7, 2025, at 11:00 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Peggy Scherle, Ph.D., Chief Scientific Officer will participate in a fireside chat. A live webcast of the ...

May 1, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Announces Presentations at 2025 AACR Annual Meeting

Prelude Announces Presentations at 2025 AACR Annual Meeting Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude’s efforts to discover and develop selective KAT6A degraders, including preclinical data, demonstrating potential for a differentiated efficacy and safety profile WILMINGTON, Del., April 25, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation o...

April 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch